Dergiler / European Journal of Rheumatology / 2017 / Cilt: 4 - Sayı: 1

Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis

Sayfa
40–45
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

For this reason, optimal protection measures should be taken and guidelines should be applied to achieve adequate metabolic control in patients with PsA

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The aim of this study was to identify the prevalence of metabolic syndrome (MetS) and degree of cardiovascular disease (CVD) risk in patients with psoriatic arthritis (PsA).Material and Methods: We performed a cross-sectional study on 102 adult patients with PsA and a control group of 102 patients with rheumatoid arthritis (RA).
📊
Temel Bulgular & Veri:The Framingham risk scores of 10-year risk of CVDs and coronary heart disease (CHD) were also calculated.
💡
Sonuç & Katkı:For this reason, optimal protection measures should be taken and guidelines should be applied to achieve adequate metabolic control in patients with PsA
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: The aim of this study was to identify the prevalence of metabolic syndrome (MetS) and degree of cardiovascular disease (CVD) risk in patients with psoriatic arthritis (PsA).Material and Methods: We performed a cross-sectional study on 102 adult patients with PsA and a control group of 102 patients with rheumatoid arthritis (RA). MetS was diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) and International Diabetes Federation (IDF) criteria. The Framingham risk scores of 10-year risk of CVDs and coronary heart disease (CHD) were also calculated. Results: The prevalence of MetS was higher in patients with PsA than in those with RA, according to the NCEP-ATP III (40.6% vs. 24.7%, respectively; p=0.019) and IDF (46.8% vs. 27.9%, respectively; p=0.05) criteria. The prevalence of MetS was higher in female patients with PsA (p=0.009) than in male patients. A significantly increased prevalence of hypertriglyceridemia was determined in patients with PsA (p=0.019). No significant difference existed between the two groups with respect to 10-year CVD (p=0.333) and CHD (p=0.798) risks. Additionally, there were no significant differences between the clinical subtypes of PsA with regard to MetS (p=0.229). Conclusion: MetS prevalence increased in patients with PsA compared with those with RA, whereas the risks were similar for CVDs and CHD. For this reason, optimal protection measures should be taken and guidelines should be applied to achieve adequate metabolic control in patients with PsA

🔖

Bu Makaleye Atıf Yap

YAZISIZ, V., YAZISIZ, H., BORLU, F., BEHLÜL, A., ÖZKAN, S. G., GÖKBELEN, Y. A. (2022). Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis. European Journal of Rheumatology, Cilt: 4 - Sayı: 1, 40–45. https://ajindex.com/articles/511739

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (5)

  1. Gelfand JM1, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005, 53: 573-7
  2. Leczinsky CG. The incidence of arthropathy in a ten-year series of psoriasis cases. Acta Derm Venereol 1948, 28: 483-7
  3. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009, 160: 1040-7. [CrossRef] 4. Gladman DD. Psoriatic arthritis. In: JH Klippel, JH Stone, LJ Crofford, PH White (eds). Primer on the Rheumatic Diseases. Springer; New York: USA; 2008: 170-193. [CrossRef] 5. Cakır N, Pamuk ÖN, Derviş E, Imeryüz N, Uslu H, Benian Ö, et al. The prevalences of some rheumatic disease in western Turkey: Havsa study. Rheumatol Int 2012; 32: 895-908. [CrossRef] 6. Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, et al. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007; 61: 548-53
  4. Oğuz A, Temizhan A, Abaci A, Kozan O, Erol C, Ongen Z, et al. Obesity and abdominal obesity; an alarming challenge for cardio-metabolic risk in Turkish adults. Anadolu Kardiyol Derg 2008; 8: 401-6
  5. Sari I, Akar S, Pakoz B, Sisman AR, Gurler O, Birlik M, et al. Hyperuricemia and its related factors in an urban population, Izmir, Turkey. Rheumatol Int 2009; 29: 869-74. [CrossRef] 9. Pehlevan S, Yetkin DO, Bahadır C, Goktay F, Pehlevan Y, Kayatas K, et al. Increased prevalence of metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 2014; 12: 43-8. [CrossRef] 10. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57: 287-293. [CrossRef] 11. Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008; 59: 1322-31. [CrossRef] 12. Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007; 36: 203-9. [CrossRef] 13. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic